Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: A meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 2250-2258

  Sakurai, Ryota ^a   Koo, Bon Kwon ^b   Kaneda, Hideaki ^c   Bonneau, Heidi N ^d   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b Seoul National University Hospital   (South Korea)

^c Okinaka Memorial Institute for Medical Research   (Japan)

^d Highlands Consulting Inc   (United States)

Author keywords

Cilostazol; Drug eluting stent; Meta analysis; Randomized controlled trial; Triple antiplatelet therapy

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PLACEBO;

ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DOSE RESPONSE; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; TREATMENT OUTCOME; VASCULAR PATENCY;

CILOSTAZOL; DRUG-ELUTING STENT; META-ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TRIPLE ANTIPLATELET THERAPY;

ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TICLOPIDINE;

EID: 84883299723     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.06.010     Document Type: Article

References (42)

1. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. J. Fajadet, W. Wijns, and G.J. Laarman Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circulation 114 2006 798 806
4. A. Kastrati, A. Dibra, and S. Eberle Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials JAMA 294 2005 819 825
5. M. Aoki, R. Morishita, and S. Hayashi Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model Diabetologia 44 2001 1034 1042
6. Y. Kubota, K. Kichikawa, and H. Uchida Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study Invest Radiol 30 1995 532 537
7. H.C. Lowe, S.N. Oesterle, and L.M. Khachigian Coronary in-stent restenosis: current status and future strategies J Am Coll Cardiol 39 2002 183 193
8. F.G. Welt, and C. Rogers Inflammation and restenosis in the stent era Arterioscler Thromb Vasc Biol 22 2002 1769 1776
9. D.B. Wilhite, A.J. Comerota, F.A. Schmieder, R.C. Throm, J.P. Gaughan, and A.K. Rao Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time J Vasc Surg 38 2003 710 713
10. S.B. King 3rd, S.C. Smith Jr., and J.W. Hirshfeld Jr. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 2008 261 295
11. I. Singh, N. Shafiq, and P. Pandhi Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query Br J Clin Pharmacol 68 2009 4 13
12. U. Tamhane, P. Meier, and S. Chetcuti Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials EuroIntervention 5 2009 384 393
13. D.L. Jennings, and J.S. Kalus Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis J Clin Pharmacol 50 2010 415 421
14. H. Takagi, and T. Umemoto A meta-analysis of randomized trials of triple versus dual antiplatelet therapy after stent-based percutaneous coronary intervention Int J Cardiol 150 2011 228 230
15. H. Takagi, and T. Umemoto Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials Int J Cardiol 153 2011 74 76
16. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
17. M.J. Sweeting, A.J. Sutton, and P.C. Lambert What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data Stat Med 23 2004 1351 1375
18. M.J. Bradburn, J.J. Deeks, J.A. Berlin, and A. Russell Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 2007 53 77
19. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
20. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
21. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
22. J.A. Sterne, D. Gavaghan, and M. Egger Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature J Clin Epidemiol 53 2000 1119 1129
23. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94
24. J.S. Douglas Jr., D.R. Holmes Jr., and D.J. Kereiakes Coronary stent restenosis in patients treated with cilostazol Circulation 112 2005 2826 2832
25. Y. Han, Y. Li, and S. Wang Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J 157 2009 733 739
26. P.K. Min, J.H. Jung, Y.G. Ko, D. Choi, Y. Jang, and W.H. Shim Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study Circ J 71 2007 1685 1690
27. Long-DES-II Study investigators Percutaneous treatment of LONG native coronary lesions with Drug-Eluting Stent-II: Cypher versus Taxus Available on crtonline.org http://www.crtonline.org/flash.aspx?PAGE-ID=3397 2012 Accessed on March, 2012
28. J.Y. Kim, K. Lee, and M. Shin Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention Circ J 71 2007 1867 1872
29. D.H. Kim, J.Y. Kim, and S.W. Moon Effects of long-term triple anti-platelet therapy with low-dose cilostazol after drug-eluting stent implantation Korean J Med 74 2008 368 375
30. D.S. Kum, M.H. Kim, and J.H. Paik Clinical effects of additional cilostazol administration after drug-eluting stent insertion Korean Circ J 39 2009 21 25
31. S.W. Lee, K.J. Chun, and S.W. Park Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials) Am J Cardiol 105 2010 168 173
32. J.W. Suh, S.P. Lee, and K.W. Park Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 2011 280 289
33. S.W. Lee, S.W. Park, and Y.H. Kim A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial J Am Coll Cardiol 57 2011 1264 1270
34. C.M. Ahn, S.J. Hong, J.H. Park, J.S. Kim, and D.S. Lim Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up Heart Vessels 26 2011 502 510
35. S.W. Lee, S.W. Park, and Y.H. Kim Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial) Am J Cardiol 100 2007 1103 1108
36. S.W. Lee, S.W. Park, and Y.H. Kim Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients) J Am Coll Cardiol 51 2008 1181 1187
37. C. Ito, E. Kusano, and Y. Furukawa Modulation of the erythropoietin- induced proliferative pathway by cAMP in vascular smooth muscle cells Am J Physiol Cell Physiol 283 2002 C1715 C1721
38. S. Hayashi, R. Morishita, and H. Matsushita Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21 Hypertension 35 2000 237 243
39. T. Inoue, T. Uchida, and M. Sakuma Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation J Am Coll Cardiol 44 2004 1408 1414
40. P. Juni, A. Witschi, R. Bloch, and M. Egger The hazards of scoring the quality of clinical trials for meta-analysis JAMA 282 1999 1054 1060
41. Y.H. Kim, S.W. Park, and S.W. Lee Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease Circulation 114 2006 2148 2153
42. S.P. Lee, J.W. Suh, and K.W. Park Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease Trials 11 2010 87